Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Marinos C. Dalakas, Allen J. Aksamit, David L. Madden, John L. Sever

Research output: Contribution to journalArticle

10 Scopus citations


Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

Original languageEnglish (US)
Pages (from-to)933-935
Number of pages3
JournalArchives of neurology
Issue number9
StatePublished - Sep 1986


ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this